Drug profile

The FDA adverse-event record for Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid

Name: Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid - FDA Animal Adverse Event Reports
Creator: PlainBreed
License: https://creativecommons.org/publicdomain/zero/1.0/

44 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid. Species, reactions, and outcomes follow.

#1201 of 2,679
by report volume (all drugs): 44
adverse-event reports: 84.1%
death-coded share: Cattle
most-reported species

Compiled by PlainBreed

Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid ranks #1198 of 2679 by total reports (44). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1): 97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1): #1198
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid has 44 reports now versus 44 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: +0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid changes

Signature read: Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid's 84.1% death-coded share is among the highest in the openFDA drug corpus.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.

Total Reports

Deaths Reported

84.1%

Death-coded share of reports

Active Ingredients

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid

Administration Routes

SubcutaneousSubconjunctivalUnknown

Species Affected

Cattle 44

Most Affected Breeds

Cattle (other) 28

Crossbred Bovine/Cattle 8

Aberdeen Angus 5

Holstein-Friesian also known as Holstein 2

Cattle (unknown) 1

Most Reported Reactions

Death 36

Respiratory signs 13

Lack of efficacy - NOS 13

NT - Abnormal necropsy finding NOS 8

Anorexia 7

Death by euthanasia 7

Lethargy (see also Central nervous system depression in 'Neurological') 6

Pneumonia 6

Fever 6

Other abnormal test result NOS 5

Nasal discharge 4

Lack of efficacy (bacteria) - NOS 4

Outcome Breakdown

Died

36 (48.6%)

Recovered/Normal

19 (25.7%)

Ongoing

8 (10.8%)

Euthanized

6 (8.1%)

Outcome Unknown

4 (5.4%)

Recovered with Sequela

1 (1.4%)

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid: high death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza3-Respiratory Syncytial Virus Vaccine, Modified Live Virus, Mannheimia Haemolytica Toxoid (#1201 of 2,679 by report volume); death-coded 84.1%. PlainBreed drug row · death-coded share stamp 84.1% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →